The Department of Veterans Affairs (VA) will give cancer claims priority when a new law takes effect in January 2023; Pfizer is looking to use its COVID-19 profits to grow other blockbusters; the probable loss of Medicaid coverage for millions next year is setting off debate.
The Department of Veterans Affairs (VA) announced that when it begins processing claims under the Honoring Our Promise to Address Comprehensive Toxics (PACT) Act in 2023, it will put veterans with cancer at the front of the line, The Hill reported. PACT expands benefits for millions of veterans who were exposed to 23 diseases, half of them cancers, assumed to be linked to burn pits or other toxins during their wartime service.
Pfizer, which has reaped nearly $100 billion from selling COVID-19 vaccines and Paxlovid to governments around the world, will use the profits to fuel the development of “potential blockbusters” for other conditions, according to a story that was originally published on Fortune and was republished on Kaiser Health News. The targets are diabetes drugs repurposed for weight loss, migraines, ulcerative colitis, prostate cancer, sickle cell disease, and obesity.
The COVID-19 public health emergency is due to expire in January 2023, and if it is not renewed, an estimate of 5 million to 14 million Americans will lose their Medicaid health coverage that was enabled by the 2020 pandemic relief bill. That is setting off a debate about what to do about people who will find themselves without health insurance, including those fall into the coverage gap in the 12 states that have not expanded Medicaid under the Affordable Care Act, Roll Call reported. Advocates of Medicaid expansion, especially in states where ballot initiatives are taking place, are attempting to sway statehouse conservatives on the long-term overall benefit of having more people insured.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More